A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies

Trial Profile

A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Birabresib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors OncoEthix
  • Most Recent Events

    • 28 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 02 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.
    • 02 Sep 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top